Board of Directors
Jaymin Amin
CEO
Mr. Jaymin Amin, B.Eng., has a successful track record of 20 years of sales, marketing and financial experience in life science start-ups.
In September 2011 Jaymin was appointed to the Board of Directors of ProfactorPharma as a non-executive director. And in August 2016 Jaymin was named, and is currently serving as the Chief Executive Officer.
Richard Cruse
CFO, Founder and Board Member
Richard is a Co-founder of PFP together with Dr Ian Garner and Prof John McVey having entered the biotech industry in 1987.
He was the company’s first CEO completing the first seed round with Kelvin Capital in 2013 and now serves as Chief Financial Officer.
Dr. David Brown
Non-Executive Chairman
Dr David Brown has over 30 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche; and also as President and Chief Executive of Cellzome AG, a biotechnology company with headquarters in Heidelberg, Germany.
David joined the Board in 2013 as part of the Kelvin Capital orchestrated investment.
Dr. V Paul Gerskowitch
Investor Director
Dr V Paul Gerskowitch joined PFP’s board as an Investor Director in August 2019. He is currently a Founder, Director and Chairman at Resolomics. Paul was a Board Director at Genometrics, the J&J-funded James Black Foundation, the MRC Collaborative Centres at both London and Edinburgh, Lectus Therapeutics, Axordia and was Director of Biomedical Research at Wyeth Research UK. Later he moved from therapeutic R&D to focus on strategic transactions within the healthcare sector.Dr. Ian Fotheringham
Non-executive Director
Ian Fotheringham received a Ph.D. in Molecular Biology with Professor David Sherratt at the University of Glasgow in 1986. Joining the NutraSweet division of Monsanto Corporation in Chicago IL, he then spent 6 years developing microbial strains for the manufacture of L-phenylalanine and the peptide sweetener Aspartame. From 1992, with NSC Technologies, Great Lakes Fine Chemicals, Richmond Chemical Corp and Ingenza, he has continued to develop large-scale industrial bioprocesses to produce chiral compounds, including non-proteinogenic amino acids and carbohydrates. He has published 30 papers and holds 7 current patents.Scientific Advisors
Professor John H McVey PhD, FRCPath
Founder & Chief Scientist
Professor McVey PhD, FRCPath has more than 20 years experience in blood coagulation factors (http://themcveylab.com/index.html) having worked with Ian Garner at Delta Biotechnology during his time at the MRC National Institute for Medical Research (Mill Hill) back in 1988/89. It was this encounter which would eventually lead to the creation of Profactor Pharma.Bruce Vernon
Director of Regulatory Affairs and QA, Founder
Bruce has a Master’s degree in Immunology and has more than 30 years experience in the development, manufacture and quality assurance and control of biological products including four years in the UK National Blood Transfusion Service and with the Nepalese Red Cross blood transfusion service. He was brought into the founding team of PFP to guide the all important regulatory aspects of biopharmaceutical product development.